{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-006505","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.433733+00:00","generated_at":"2026-06-16T09:27:55.335555+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MAIA Biotechnology closes $5.75M public offering to fund THIO trials and R&D","bullets":["Gross proceeds of ~$5.75M from 2,555,500 shares at $2.25/share, including full over-allotment exercise.","Net proceeds of ~$5.1M after underwriting discounts and expenses; intended for THIO trials and telomere compound development.","Representative's warrants to purchase up to 127,775 shares at $2.8125/share, exercisable from Oct 2023 to Apr 2028.","ThinkEquity acted as sole book-running manager for the offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-006505","json":"https://secwatch.observer/filing/0001564590-23-006505.json","markdown":"https://secwatch.observer/filing/0001564590-23-006505.md","text":"https://secwatch.observer/filing/0001564590-23-006505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000156459023006505/0001564590-23-006505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000156459023006505/maia-8k_20230424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T09:27:55.335555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7d43ea7962408ef278642ebd79b276143d97f74","claim":"MAIA Biotechnology, Inc. entered into Underwriting Agreement with ThinkEquity LLC valued at aggregate net proceeds of approximately $5.1 million (effective 2023-04-24).","evidence_excerpt":"On April 24, 2023, MAIA Biotechnology, Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC, as representative (the “Representative”) of the several underwriters identified therein","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1878313/000156459023006505/0001564590-23-006505-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"ThinkEquity LLC"},{"label":"Value","value":"aggregate net proceeds of approximately $5.1 million"},{"label":"Effective","value":"2023-04-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}